Abstract: Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.

Abstract: A terminal modified polybutylene terephthalate resin has a weight average molecular weight Mw of 10,000 to 100,000, a melting point of 210° C. to 235° C., and a melt viscosity ? at 250° C. of not more than 10 Pa·s, and includes 90 to 300 mol/ton of a compound having a (poly)oxyalkylene structure, the compound being terminally bound in the resin, wherein the weight average molecular weight Mw represents a relative weight average molecular weight with respect to the molecular weight of a standard poly(methyl methacrylate) as determined by gel permeation chromatography using hexafluoroisopropanol (supplemented with 0.005 N sodium trifluoroacetate) as a mobile phase.

Abstract: The present invention relates to a transparent copolyester, wherein the transparent copolyester comprises an aliphatic-aromatic copolyester segment A, a segment B having repeating units —O—CH(CH3)—C(O)—, and structural units C derived from polyisocyanate(s), wherein the weight ratio for the segment A, segment B and structural unit C is 100:(100-2000):(0.1-10) and wherein the weight-average molecular weight Mw of the transparent copolyester is from 50,000 to 1,000,000. The present invention further relates to a preparation method for a transparent copolyester, including polymerizing lactide, a hydroxyl-terminated aliphatic-aromatic copolyester and a polyisocyanate in the presence of a catalyst; wherein the weight ratio for the aliphatic-aromatic copolyester, lactide and polyisocyanate is 100:(100-2000):(0.1-10). The present invention further relates to a transparent copolyester prepared by said method and an article made from the transparent copolyester according to present invention.

Abstract: A polylactic acid composition is produced with an MI value of 0.05 or more and 5 or less, the MI value being measured at 190° C. under a load of 21.6 kg in accordance with JIS K7210 (ISO 1133). A polylactic acid is crosslinked with a polyisocyanate to generate a cross-linked polylactic acid, including a large cross-linked polylactic acid molecule which inhibits foaming. The cross-linked polylactic acid is mechanically grinded-by applying a shear force to decrease a molecular weight of the large cross-linked polylactic acid molecule. The amount of the polyisocyanate combined is 0.4 to 5% by weight based on the polylactic acid. The grinding is conducted in supercritical condition of an inert gas. A foam molded article is made from the polylactic acid composition.

Abstract: The present invention relates to a supramolecular polymer comprising 1-50 4H-units, said supramolecular polymer being obtainable by reacting at least one monomeric building block with a prepolymer. The present invention further relates to articles or compositions comprising the supramolecular polymer, in particular articles or compositions selected from the group consisting of decorative, thermo-reversible, or self-healing coatings, adhesive compositions, sealing compositions, thickeners, gelators and binders.

Abstract: The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included in the molecular assembly being released from the molecular assembly by an external environmental change. The present invention utilizes a phenomenon that the hydrophilic-hydrophobic balance of the amphiphilic molecules is shifted toward hydrophilicity by an external environmental change and thus the amphiphilic molecules are freed from the molecular assembly.

Abstract: The present invention relates to a process for the preparation of polyether carbonate polyols with primary hydroxyl end groups, comprising the steps of reaction of a starter compound containing active hydrogen atoms with an epoxide and carbon dioxide under double metal cyanide catalysis, reaction of the product obtained with a cyclic carboxylic acid anhydride and reaction of this product obtained with ethylene oxide in the presence of a catalyst which contains at least one nitrogen atom per molecule, excluding non-cyclic tertiary amines with identical substituents. The invention furthermore relates to polyether carbonate polyols obtainable by this process, compositions comprising these polyether carbonate polyols and polyurethane polymers based on these polyether carbonate polyols.

Abstract: The invention relates to novel molded polyurethane elastomer parts made of diphenylmethane diisocyanate-based NCO-functional prepolymers and diphenylmethandiamine blocked with metal salts and to a method for producing same.

Abstract: An object of the present invention is to inexpensively provide a method and device of producing a high viscosity polylactic acid composition, which composition is appropriate for foam molding having a high expansion ratio and is stable, and a foam molded article having a high expansion ratio formed of said high viscosity polylactic acid composition. A method of producing a polylactic acid foam molded article of the present invention which can achieve the above-described object is characterized by comprising a step of mechanically grinding a polylactic acid composition by applying a shear force, using a device equipped with an injection molding machine (B) or an extrusion molding machine (G), an orifice portion (S) and a foaming mold (P), in a foaming gas atmosphere in the orifice portion (S).

Abstract: The present invention relates to biodegradable aliphatic-aromatic polyesters obtained from aliphatic dicarboxylic acids, polyfunctional aromatic acids and diols, wherein the polyfunctional aromatic acids are constituted by mixtures of acids of renewable and synthetic origin.

Abstract: Process of modifying polylactic acid and compositions formed therefrom are described herein. The process generally includes providing a first polylactic acid, wherein the first polylactic acid includes a carboxylic acid end group and unsaturating the first polylactic acid to form a second polylactic acid.

Abstract: The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included in the molecular assembly being released from the molecular assembly by an external environmental change. The present invention utilizes a phenomenon that the hydrophilic-hydrophobic balance of the amphiphilic molecules is shifted toward hydrophilicity by an external environmental change and thus the amphiphilic molecules are freed from the molecular assembly.

Abstract: The current invention relates to devices and methods for protecting drugs coated on implantable medical devices, in particular drug-eluting stents, involving the inclusion of free or, preferably at present, polymer-bound stable nitroxides in a coating layer on the device that is either the same layer that contains the drug or that is located between the drug-containing layer and the source of free electrons used to sterilize the device.

Abstract: The present invention relates to implantable medical devices comprising poly(ester-amide) elastomers in coating layers on the device.

Abstract: The current invention relates to physically crosslinked block copolymers, in particular triblock copolymers in which the end blocks are capable of physical crosslinking.

Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric carrier regions. These polymeric carrier regions, in turn, contain a polymer, a low solubility therapeutic agent, and a solubilizing agent.

Abstract: A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.